Gilead, Arcus’ PhII gastroesophageal cancer data argue for TIGIT antibody drug class potential

Gilead and part­ner Ar­cus Bio­sciences’ an­ti-TIG­IT-based reg­i­men has shown ear­ly signs of ef­fi­ca­cy in a small group of gas­troe­sophageal can­cer pa­tients in a mid-stage tri­al, mark­ing a po­ten­tial up­lift for the TIG­IT field af­ter a track record of set­backs.

The Phase II EDGE-Gas­tric tri­al is eval­u­at­ing dif­fer­ent com­bi­na­tions of dom­vanal­imab plus Ar­cus’ an­ti-PD-1 an­ti­body zim­bere­limab and stan­dard-of-care chemother­a­py in cer­tain types of gas­troe­sophageal can­cer. Dom­vanal­imab is a mon­o­clon­al an­ti­body that blocks the TIG­IT pro­tein re­cep­tor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.